Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Chromatin Biology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SET/TAF-I drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SET/TAF-I Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli expressed for structural integrity. |
View SET Products |
| Gene Delivery | SET/TAF-I Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View SET Products |
| Benchmark Ab | Anti-SET/TAF-I Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View SET Products |
| Validator | SET/TAF-I siRNA Set For knockdown verification and functional rescue assays. |
View SET Products |
| Related Target A | PP2A (PPP2CA) Direct binding partner. SET acts as a potent inhibitor of PP2A, driving oncogenic signaling. |
View PP2A Products |
| Related Target B | CIP2A Synergistic PP2A inhibitor in solid tumors; critical for dual-targeting pathway analysis. |
View CIP2A Products |
| Related Target C | MYC Downstream oncogenic driver stabilized by SET-mediated PP2A inhibition. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening | High-purity SET and PP2A catalytic subunits with verified sequence identity and low aggregate profiles. |
| Off-target histone chaperone screening | Truncated SET domain variants designed for specificity screening against histone chaperoning vs. PP2A inhibition. |
| Lack of Controls | Sequence-verified benchmark antibodies and validated siRNA knockdowns included. |
| False Positives in PPI | Endotoxin-controlled, aggregation-free recombinant proteins minimize non-specific assay interference. |
Live SET/TAF-I R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SET/TAF-I therapeutics is intensifying, with major players shifting focus from traditional peptide-based disruptors to small-molecule inhibitors and PROTACs (Proteolysis Targeting Chimeras). As first-generation SET-PP2A interaction disruptors (such as OP449/CODA-22) demonstrate proof-of-concept in hematological malignancies, the next wave of R&D is targeting selective degradation of SET to fully restore PP2A tumor suppressor activity and overcome drug resistance in leukemia and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Disruptor) | Academic Consortia, Biotech Startups | AML, CML, Prostate Cancer | Disruption Assay (Need high-purity, aggregation-free SET and PP2A proteins) |
| Peptidomimetic | Oncology-focused Biopharma | Lymphoma, Breast Cancer | Cellular uptake and binding affinity validation (Need stable cell lines via Lentivirus) |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) Pioneers | Refractory Solid Tumors, Kinase-resistant Leukemia | Degradation kinetics and selectivity screening (Need Mutant vs WT SET proteins and siRNA validators) |